Massachusetts General Hospital, Bartlett Hall 500R, 55 Fruit Street, Boston, MA, 02114, USA,
Drug Deliv Transl Res. 2012 Jun;2(3):201-9. doi: 10.1007/s13346-012-0073-3.
Presently, there are no effective treatments for several diseases involving the central nervous system (CNS). While several novel molecular approaches are being developed, many of them require delivery of macromolecular or supramolecular agents to the CNS tissues protected by the blood-brain and blood-arachnoid barriers. A variety of approaches that are being developed for overcoming or bypassing the barriers are based on complex transfer processes. The delivery of biopharmaceuticals and other macromolecules and particulates to the CNS, especially through the leptomeningeal (intrathecal) route, includes a variety of stages, such as leptomeningeal propagation, drainage to the systemic circulation, and penetration into the CNS. The investigation of complex pharmacokinetics that includes convective, as well as diffusional and active transfer processes, greatly benefit from real-time non-invasive in vivo monitoring of the drug transport. Pharmacological positron emission tomography (PET) imaging, which enables such monitoring, plays an increasingly significant role in drug delivery and biopharmacology. PET is a powerful tool for quantitative in vivo tracking of molecules labeled with positron-emitting radionuclides. The high sensitivity, format, and accuracy of the data (similar to those of conventional tissue sampling biodistribution studies) make PET a readily adoptable pharmacological technique. In contrast to the conventional studies, PET also allows for longitudinal nonterminal same-animal studies. The latter may not only improve the data statistics, but also enable preclinical studies (especially in large and/or rare animals) not feasible under the conventional approach. This paper is intended to demonstrate the character of data that can be obtained by PET and to demonstrate how the main patterns of the leptomeningeal route pharmacokinetics can be investigated using this method. Examples of data processing are taken from our recent studies of five model proteins in rats and nonhuman primates.
目前,针对涉及中枢神经系统(CNS)的几种疾病,尚无有效的治疗方法。虽然正在开发几种新型分子方法,但其中许多方法需要将大分子或超分子药物递送到受血脑和血脑屏障保护的 CNS 组织中。为克服或绕过这些屏障而开发的各种方法基于复杂的传递过程。生物制药和其他大分子和颗粒物质向 CNS 的递送,特别是通过脑膜(鞘内)途径的递送,包括多种阶段,例如脑膜传播、向全身循环的引流以及穿透 CNS。对包括对流以及扩散和主动转运过程在内的复杂药代动力学的研究,从实时非侵入性体内药物转运监测中受益匪浅。能够进行这种监测的药理学正电子发射断层扫描(PET)成像在药物输送和生物药理学中发挥着越来越重要的作用。PET 是用正电子发射放射性核素标记的分子进行定量体内追踪的强大工具。数据的高灵敏度、格式和准确性(类似于常规组织采样生物分布研究)使 PET 成为一种易于采用的药理学技术。与传统研究相比,PET 还允许进行非终端纵向同动物研究。后者不仅可以改善数据统计,还可以在常规方法不可行的情况下进行临床前研究(尤其是在大型和/或稀有动物中)。本文旨在展示通过 PET 获得的数据的特征,并展示如何使用该方法研究脑膜途径药代动力学的主要模式。数据处理的示例取自我们最近在大鼠和非人灵长类动物中对五种模型蛋白的研究。